|
Quotes & Info
|
| SENO > SEC Filings for SENO > Form 8-K on 11-Jun-2009 | All Recent SEC Filings |
11-Jun-2009
Other Events, Financial Statements and Exhibits
At its meeting held on June 9, 2009, the Board of Directors of SenoRx, Inc. took the following actions effective immediately:
Appointment of Chairman of the Board of Directors
The Board appointed Lloyd H. Malchow, our current President, Chief Executive Officer and Director, as Chairman of the Board. Mr. Malchow will receive no additional compensation for serving as Chairman.
Appointment of Lead Independent Director
The Board appointed A. Thomas Bender, an independent director, to the newly-created position of Lead Independent Director. Mr. Bender will receive no additional compensation for serving as Lead Independent Director. Mr. Bender will also continue to serve as the Chair of our Compensation Committee.
Creation of Nominating and Corporate Governance Committee
The Board formed a Nominating and Corporate Governance Committee comprised of three independent directors and adopted a charter for this committee. The members of this committee are Vickie L. Capps (Chair), John L. Erb and Frederick J. Dotzler. The Board has delegated to this committee authority over corporate governance generally, Board composition, evaluation and nominating activities, Board committee composition and conflicts of interest. A copy of this committee's charter is attached hereto as Exhibit 99.1 and will be available on our website at www.senorx.com. We have previously disclosed the compensation that we will pay for participation on this committee.
Background information related to these corporate governance updates
Before the creation of this new committee, all of the independent members of our Board were responsible for nominating and corporate governance affairs. Following a formal Board self-assessment procedure that we conducted last year, management was guided to begin analyzing possible changes to our nominating and corporate governance oversight process. As we are now becoming a larger and more mature company, we determined that this was now the appropriate time to formalize these responsibilities and delegate to a specific sub-set of our Board by creating the Nominating and Corporate Governance Committee. During this process of self-assessment and analysis, we also determined that it was appropriate to create the position of Lead Independent Director within our Board. These changes, together with the appointment of Mr. Malchow as the Chairman of our Board, are all part of our long-term succession planning strategy and institutionalizing the responsibility over such matters.
(d) Exhibits.
Exhibit No. Description
99.1 SenoRx, Inc. Nominating and Corporate Governance Committee Charter.
|
|